French National Registry of Bone Marrow Failures

Last updated: March 1, 2021
Sponsor: Assistance Publique - Hôpitaux de Paris
Overall Status: Active - Recruiting

Phase

N/A

Condition

Aplastic Anemia

Treatment

N/A

Clinical Study ID

NCT04781790
NI17045J
  • All Genders

Study Summary

This is a unique clinical and biological database that collects standardized clinical information during the management of all patients with bone marrow failure syndromes (BMF) in France (multicenter registry), from diagnosis and throughout follow-up during the natural history of the disease, treated or not. In parallel, biological samples (blood and/or bone marrow and/or skin) are collected during clinical care and are biobanked in Saint-Louis Hospital (Hematology laboratory) in order to be used in translational research related to bone marrow failure diseases.

This registry has two main objectives:

  • Public health care evaluation and improvement: to assess the medical and social needs inherent to the management of these rare diseases; to precisely assess the level of diagnosis and management of bone marrow failure syndromes in France; to evaluate the impact and guidance of the French reference center guidelines for diagnosis and treatment; to evaluate the real-life efficacy and tolerance of any given specific treatments; to analyze treatment's cost-effectiveness according to each situation.

  • Research:

    • Epidemiology: to determine the incidence, prevalence, and distribution of different bone marrow failure syndromes at the national level;

    • Biology: to better understand the pathophysiology of BMF; to identify and to study complications within each entity, such as mechanisms underlying clonal evolution, new forms of inherited BMF and acute myeloid leukemia (AML)/MDS-predisposition syndromes, and to better and deeper characterize known entities;

    • Treatment: to identify prognostic factors and predictors of response; to identify side effects and impact of treatment on others organs and natural functions; to assess patients' quality of life as early as possible since diagnosis and throughout follow-up.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • All age
  • All diagnostic of BMF
  • Having given his non-opposition to registry after understand overall aims
  • Having signed a written informed consent (2 parents for patients aged less than 18)for collection of biological samples
  • With health insurance coverage

Exclusion

Exclusion Criteria: With myelodysplastic syndrome occurring in a patient over the age of 50 in absence ofgenetical predispositions, familial forms and history of medullary hypoplasia

Study Design

Total Participants: 5000
Study Start date:
February 06, 2017
Estimated Completion Date:
February 06, 2027

Connect with a study center

  • Hématologie Greffe

    Paris,
    France

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.